3. Umbruch 4.4..2005 - Online Pot

Cannabinoid targets for pain therapeutics 163
fatty acid amide of endocannabinoid signaling. Neuroscience 119: 481–496
99 Egertová M, Giang DK, Cravatt BF, Elphick MR (1998) A new perspective on cannabinoid signalling:
complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat
brain. Proc R Soc Lond B Biol Sci 265: 2081–2085
100 Tsou K, Nogueron MI, Muthian S, Sanudo-Pena MC, Hillard CJ, Deutsch DG, Walker JM (1998)
Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system
as revealed by immunohistochemistry. Neurosci Lett 254: 137–140
101 Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001)
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking
fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371–9376
102 Lichtman AH, Shelton CC, Advani T, Cravatt BF (2004) Mice lacking fatty acid amide hydrolase
exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109: 319–327
103 Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G, Omeir RL, Makriyannis A
(1997) Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid
receptor. Biochem Biophys Res Commun 231: 217–221
104 Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z, Howlett A. (1997)
Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase.
Biochem Pharmacol 53: 255–260
105 Bisogno T, Melck D, De Petrocellis L, Bobrov MY, Gretskaya NM, Bezuglov VV, Sitachitta N,
Gerwick WH, Di Marzo V (1998) Arachidonoylserotonin and other novel inhibitors of fatty acid
amide hydrolase. Biochem Biophys Res Commun 248: 515–522
106 Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ,
Patricelli MP, Cravatt BF (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase:
the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl
Acad Sci USA 97: 5044–5549
107 Boger DL, Miyauchi H, Hedrick MP (2001) alpha-Keto heterocycle inhibitors of fatty acid amide
hydrolase: carbonyl group modification and alpha-substitution. Bioorg Med Chem Lett 11:
1517–1520
108 Leung D, Hardouin C, Boger DL, Cravatt BF (2003) Discovering potent and selective reversible
inhibitors of enzymes in complex proteomes. Nat Biotechnol 21: 687–691
109 Lichtman AH, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D, Cravatt BF (2004)
Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an
unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441–448
110 Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role
of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:
1094–1097
111 De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000) Overlap between the ligand
recognition properties of the anandamide transporter and the VR1 vanilloid receptor:
inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483: 52–56
112 Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V (2003) Novel selective and metabolically
stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65: 1473–1481
113 Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fowler CJ, Tiger G, de Lago E,
Fernandez-Ruiz J, Ramos JA (2003) Design, synthesis and biological evaluation of new endocannabinoid
transporter inhibitors. Eur J Med Chem 38: 403–412
114 Ruiz-Llorente L, Ortega-Gutierrez S, Viso A, Sanchez MG, Sanchez AM, Fernandez C, Ramos
JA, Hillard C, Lasuncion MA, Lopez-Rodriguez ML, Diaz-Laviada I (2004) Characterization of
an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter
inhibitors as tools for this study. Br J Pharmacol 141: 457–467
115 Ghosh P, Bhattacharya SK (1979) Cannabis-induced potentiation of morphine analgesia in rat –
role of brain monoamines. Indian J Med Res 70: 275–280
116 Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids
alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262: 10–18
117 Smith FL, Cichewicz D, Martin ZL, Welch SP (1998) The enhancement of morphine antinociception
in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 60: 559–566
118 Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life
Sci 74: 1317–1324
119 Cichewicz DL, McCarthy EA (2003) Antinociceptive synergy between delta(9)-tetrahydrocannabinol
and opioids after oral administration. J Pharmacol Exp Ther 304: 1010–1015